16th Sep 2015 07:01
LONDON (Alliance News) - Horizon Discovery Group PLC on Wednesday said its bioproduction business has signed a licensing deal with contract research organisation LakePharma Inc.
The agreement covers the commercial use of a genetically-engineered Chinese Hamster Ovary cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.
"The licence agreement with LakePharma, the first of its kind, serves as recognition and validation of our approach to developing novel bioproduction cell lines," said Horizon Chief Executive Darrin Disley.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
HZD.L